CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment with SB216763 led to an almost complete suppression of CML LSCs when combined with imatinib but not dasatinib, whereas it had no effects in CD34+ HSCs from healthy donors [112].